Abstract
BACKGROUND
Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored.
METHODS
The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site.
RESULTS
Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice.
CONCLUSION
It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc).
TY - JOUR
T1 - Targeted Delivery of Colloidal Silver for MCF-7 Breast Cancer Treatment.
AU - Rajawat,Shweta,
AU - Malik,Manzar M,
PY - 2020/01/30/received
PY - 2020/03/11/revised
PY - 2020/04/07/accepted
PY - 2020/5/10/pubmed
PY - 2020/5/10/medline
PY - 2020/5/9/entrez
KW - Adriamycin
KW - MCF-7 breast cancer
KW - black tea leaves extract
KW - multi surface coatings
KW - potato extract
KW - silver nanoparticles
KW - targeted delivery
SP - 613
EP - 621
JF - Current drug delivery
JO - Curr Drug Deliv
VL - 17
IS - 7
N2 - BACKGROUND: Amongst various cancer diseases, breast cancer is frequently diagnosed malignancy in women. Existing treatments are inadequate, painful and toxic. New ways of treatments need to be explored. METHODS: The present work proposes preparation and targeted delivery of a formulation, F-1, for MCF-7 breast cancer treatment. The formulation, colloidal silver (0.76 ppm), was prepared by electrolytic deposition technique and multi surface coatings. Black tea extract (2.25%v/v) was used as a capping agent to tune the morphology of silver nanoparticle and potato extract (6.25%v/v) as a functionalizing agent for targeting MCF-7 breast cancer site. RESULTS: Characterization results show highly pure spherical silver nanoparticles with an average particle size of 15nm. The shift of peaks in the FTIR spectra of formulation confirms the interaction between nanoparticles and extracts. The UV-visible peak was obtained at 525nm, a typical characteristic of silver nanoparticles. In-vivo; anti-cancer study of formulation gave a moderate therapeutic effect in Non-Obese Diabetic Severe Combined Immune Deficiency (NOD-SCID) mice. CONCLUSION: It is observed that tumor volumes obtained in the case of Formulation-1 were moderately inhibited from days 5 to 9. However, one of the mice in the Formulation-1 group inhibited tumor volume to 1.52 cc similar to one of the mice of positive control group (Adriamycin 1.42cc).
SN - 1875-5704
UR - https://www.unboundmedicine.com/medline/citation/32384028/Targeted_Delivery_of_Colloidal_Silver_for_MCF-7_Breast_Cancer_Treatment
L2 - https://www.eurekaselect.com/181779/article
DB - PRIME
DP - Unbound Medicine
ER -
